Technical Analysis for APRE - Aprea Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 3.35 | 1.53% | 0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | 1.53% | |
| Calm After Storm | Range Contraction | 1.53% | |
| NR7 | Range Contraction | 1.53% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 17 hours ago |
| Rose Above Lower Bollinger Band | about 17 hours ago |
| Rose Above 50 DMA | about 17 hours ago |
| Outside Day | about 17 hours ago |
| Up 3% | about 17 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.1501 |
| Average Volume | 26,641 |
| 200-Day Moving Average | 4.66 |
| 50-Day Moving Average | 3.34 |
| 20-Day Moving Average | 3.91 |
| 10-Day Moving Average | 3.70 |
| Average True Range | 0.36 |
| RSI (14) | 42.53 |
| ADX | 26.28 |
| +DI | 15.01 |
| -DI | 22.74 |
| Chandelier Exit (Long, 3 ATRs) | 3.94 |
| Chandelier Exit (Short, 3 ATRs) | 4.22 |
| Upper Bollinger Bands | 4.54 |
| Lower Bollinger Band | 3.28 |
| Percent B (%b) | 0.06 |
| BandWidth | 32.34 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.13 |
| MACD Histogram | -0.1135 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.71 | ||||
| Resistance 3 (R3) | 3.70 | 3.56 | 3.65 | ||
| Resistance 2 (R2) | 3.56 | 3.47 | 3.57 | 3.63 | |
| Resistance 1 (R1) | 3.45 | 3.41 | 3.51 | 3.47 | 3.61 |
| Pivot Point | 3.32 | 3.32 | 3.34 | 3.32 | 3.32 |
| Support 1 (S1) | 3.21 | 3.22 | 3.26 | 3.23 | 3.09 |
| Support 2 (S2) | 3.07 | 3.17 | 3.08 | 3.07 | |
| Support 3 (S3) | 2.97 | 3.07 | 3.05 | ||
| Support 4 (S4) | 2.99 |
